Hazel M. Aker

This profile gathers the share dealings of Hazel M. Aker across 3 companies, led by Cadence Pharmaceuticals Inc, Oncternal Therapeutics, Inc. and Cancervax Corp. In total, 17 filings cover trades dated from 20 March 2006 to 21 July 2020.

On the open market, the record shows 1 purchase worth €87k and 6 sales worth €475k. On balance, insiders were net sellers of €389k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants and 5 option exercises. So far in 2020, the count stands at 1 purchase and no sales.

On 23 July 2020 came the latest disclosure, an open-market purchase for €87k in Oncternal Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.